Advertisement

ResearchIn-Press PreviewGeneticsMuscle biology Open Access | 10.1172/jci.insight.160516

DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via a subcutaneous administration

Tejal Aslesh,1 Esra Erkut,2 Jun Ren,3 Kenji Rowel Q. Lim,2 Stanley Woo,2 Susan Hatlevig,4 Hong M. Moulton,4 Simon Gosgnach,3 John Greer,3 Rika Maruyama,2 and Toshifumi Yokota2

1Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada

2Department of Medical Genetics, University of Alberta, Edmonton, Canada

3Department of Physiology, University of Alberta, Edmonton, Canada

4Department of Biomedical Sciences, Oregon State University, Corvallis, United States of America

Find articles by Aslesh, T. in: JCI | PubMed | Google Scholar |

1Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada

2Department of Medical Genetics, University of Alberta, Edmonton, Canada

3Department of Physiology, University of Alberta, Edmonton, Canada

4Department of Biomedical Sciences, Oregon State University, Corvallis, United States of America

Find articles by Erkut, E. in: JCI | PubMed | Google Scholar |

1Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada

2Department of Medical Genetics, University of Alberta, Edmonton, Canada

3Department of Physiology, University of Alberta, Edmonton, Canada

4Department of Biomedical Sciences, Oregon State University, Corvallis, United States of America

Find articles by Ren, J. in: JCI | PubMed | Google Scholar

1Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada

2Department of Medical Genetics, University of Alberta, Edmonton, Canada

3Department of Physiology, University of Alberta, Edmonton, Canada

4Department of Biomedical Sciences, Oregon State University, Corvallis, United States of America

Find articles by Lim, K. in: JCI | PubMed | Google Scholar |

1Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada

2Department of Medical Genetics, University of Alberta, Edmonton, Canada

3Department of Physiology, University of Alberta, Edmonton, Canada

4Department of Biomedical Sciences, Oregon State University, Corvallis, United States of America

Find articles by Woo, S. in: JCI | PubMed | Google Scholar |

1Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada

2Department of Medical Genetics, University of Alberta, Edmonton, Canada

3Department of Physiology, University of Alberta, Edmonton, Canada

4Department of Biomedical Sciences, Oregon State University, Corvallis, United States of America

Find articles by Hatlevig, S. in: JCI | PubMed | Google Scholar

1Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada

2Department of Medical Genetics, University of Alberta, Edmonton, Canada

3Department of Physiology, University of Alberta, Edmonton, Canada

4Department of Biomedical Sciences, Oregon State University, Corvallis, United States of America

Find articles by Moulton, H. in: JCI | PubMed | Google Scholar

1Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada

2Department of Medical Genetics, University of Alberta, Edmonton, Canada

3Department of Physiology, University of Alberta, Edmonton, Canada

4Department of Biomedical Sciences, Oregon State University, Corvallis, United States of America

Find articles by Gosgnach, S. in: JCI | PubMed | Google Scholar

1Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada

2Department of Medical Genetics, University of Alberta, Edmonton, Canada

3Department of Physiology, University of Alberta, Edmonton, Canada

4Department of Biomedical Sciences, Oregon State University, Corvallis, United States of America

Find articles by Greer, J. in: JCI | PubMed | Google Scholar

1Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada

2Department of Medical Genetics, University of Alberta, Edmonton, Canada

3Department of Physiology, University of Alberta, Edmonton, Canada

4Department of Biomedical Sciences, Oregon State University, Corvallis, United States of America

Find articles by Maruyama, R. in: JCI | PubMed | Google Scholar |

1Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada

2Department of Medical Genetics, University of Alberta, Edmonton, Canada

3Department of Physiology, University of Alberta, Edmonton, Canada

4Department of Biomedical Sciences, Oregon State University, Corvallis, United States of America

Find articles by Yokota, T. in: JCI | PubMed | Google Scholar

Published January 31, 2023 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.160516.
Copyright © 2023, Aslesh et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published January 31, 2023 - Version history
View PDF
Abstract

Antisense oligonucleotide (AO)-mediated therapy is a promising strategy to treat several neurological diseases including spinal muscular atrophy (SMA). However, limited delivery to the central nervous system (CNS) with AOs administered intravenously or subcutaneously is a major challenge. Here we demonstrate a single subcutaneous administration of cell-penetrating peptide DG9 conjugated to an AO called phosphorodiamidate morpholino oligomers (PMOs) reaches the CNS and significantly prolonged the median survival compared to unconjugated PMO and R6G-PMO in a severe SMA mouse model. Treated mice exhibited significantly higher expression of full-length SMN2 expression (FL-SMN2) in both the CNS and systemic tissues compared to non-treated and unmodified AO-treated mice. The treatment ameliorated the atrophic musculature and improved breathing function accompanied by improved muscle strength and innervation at the neuromuscular junction with no signs of apparent toxicity. We also demonstrated DG9-conjugated PMO localizes in nuclei in the spinal cord and brain after subcutaneous injections. Our data identify DG9 peptide conjugation as a powerful way to improve the efficacy of AO-mediated splice modulation. Finally, DG9-PMO is a promising therapeutic option to treat SMA and other neurological diseases, overcoming the necessity for intrathecal injections and treating body-wide tissues without apparent toxicity.

Graphical Abstract
graphical abstract
Supplemental material

View

Version history
  • Version 1 (January 31, 2023): In-Press Preview
  • Version 2 (March 8, 2023): Electronic publication
Advertisement
Advertisement